Abstract
Chronic myeloid leukemia (CML) patients in sustained “deep molecular response” may stop TKI treatment without disease recurrence; however, half of them lose molecular response shortly after TKI withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still missing. Relapse is probably due to residual quiescent TKI-resistant leukemic stem cells (LSCs) supposedly transcriptionally low/silent and not easily detectable by BCR-ABL1 qRT-PCR. Bone marrow Ph+ CML CD34+/CD38− LSCs were found to specifically co-express CD26 (dipeptidylpeptidase-IV). We explored feasibility of detecting and quantifying CD26+ LSCs by flow cytometry in peripheral blood (PB). Over 400 CML patients (at diagnosis and during/after therapy) entered this cross-sectional study in which CD26 expression was evaluated by a standardized multiparametric flow cytometry analysis on PB CD45+/CD34+/CD38− stem cell population. All 120 CP-CML patients at diagnosis showed measurable PB CD26+ LSCs (median 19.20/μL, range 0.27–698.6). PB CD26+ LSCs were also detectable in 169/236 (71.6%) CP-CML patients in first-line TKI treatment (median 0.014 cells/μL; range 0.0012–0.66) and in 74/112 (66%), additional patients studied on treatment-free remission (TFR) (median 0.015/μL; range 0.006–0.76). Notably, no correlation between BCR-ABL/ABLIS ratio and number of residual LSCs was found both in patients on or off TKIs. This is the first evidence that “circulating” CML LSCs persist in the majority of CML patients in molecular response while on TKI treatment and even after TKI discontinuation. Prospective studies evaluating the dynamics of PB CD26+ LSCs during TKI treatment and the role of a “stem cell response” threshold to achieve and maintain TFR are ongoing.
Highlights
For many years since their appearance in the treatment scenario of chronic myeloid leukemia (CML), TKIs have been an extraordinary highly effective life-long treatment [1, 2]
120 newly diagnosed CML patients were tested for circulating peripheral blood (PB) CD26+leukemic stem cells (LSCs)
We clearly demonstrated that 100% of CML patients at diagnosis show CML-specific CD26+ LSCs and that CD26+ LSCs absolute number is superimposable in PB and BM samples allowing us to quantify LSCs directly in PB
Summary
For many years since their appearance in the treatment scenario of chronic myeloid leukemia (CML), TKIs have been an extraordinary highly effective life-long treatment [1, 2]. Warfving and colleagues revealed a great heterogeneity of BM LSCs through the combination of flow cytometry and single-cell molecular analysis; the crucial role of CD26 antigen was confirmed by the evidence that most insensitive TKI cells of the BM LSC compartment were defined by a specific Lin−CD34+CD38−/lowCD 45RA−cKIT−CD26+ phenotype [21] Based on these evidences, considering that routine monitoring of residual LSCs from bone marrow is not practical, the present study aims were: (i) to explore the feasibility of CD26+LSC flow cytometry evaluation in peripheral blood (PB) in CML patients; (ii) to quantify circulating LSCs during TKI treatment and during TKI discontinuation, and (iii) to search a correlation, if any, between number of residual LSCs and molecular response (BCR-ABL/ABL1IS ratio).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have